Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Description:
Cancer vaccines are being developed as a method of preventing certain types of cancer, and as therapeutic treatments to treat existing cancers across a range of indications in oncology, either as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery. The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies, which have a lower toxicity associated with their use than traditional chemotherapies.

Therapeutic vaccine administration will increase the overall survival of poor-performance-status patients, and enable more rounds of treatment to be given - factors that will contribute to growing global revenues for this class of therapy. However, cancer vaccines are not perceived as having strong commercial potential, as immune checkpoint inhibitors are expected to dominate the treatment landscape for leukemia and lymphoma during the forecast period.

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive cancer prevalence and revenue growth for its treatments.

Prophylactic vaccines are currently used to immunize against viruses, which have been shown to increase the risk of cancer, with viral factors being the underlying cause of approximately 15% of cancers worldwide. Prophylactic vaccines such as Gardasil are currently the most commercially successful and well-established class of cancer vaccines. However, there has been a shift towards the clinical testing of therapeutic vaccines - which constitute the majority of the pipeline - such as Imlygic, which was recently approved for melanoma.

Scope
- Global revenues for the cancer vaccines market are forecast to grow at a compound annual growth rate (CAGR) of 16.93%, from $2.5 billion in 2015 to $7.5 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The cancer vaccine pipeline is large and fairly diverse, and contains 1,286 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular molecule types and molecular targets in the pipeline?
- What mechanisms of action and molecule types are most common for pipeline vaccines being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 pharma companies compare within cancer vaccines?
- What proportion of the key players' revenues will be attributable to cancer vaccines?

Reasons to buy
This report will allow you to:
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the cancer vaccines market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the cancer vaccine pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the cancer vaccine market globally and across the key players and product types
- Stratify the market in terms of the split between therapeutic and prophylactic vaccines, and assess the role of these product types in the treatment of the various cancers
Identify commercial opportunities in the cancer vaccine deals landscape by analyzing trends in licensing and co-development deals

Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
   2.3.1 Etiology
   2.3.2 Cancer Pathophysiology
   2.3.3 Virus Pathophysiology
2.4 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
   2.4.1 Cervical Cancer
   2.4.2 Liver Cancer
   2.4.3 Melanoma
   2.4.4 Prostate Cancer
2.5 Co-morbidities and Complications
2.6 Treatment
   2.6.1 Surgery and Radiation Therapy
   2.6.2 Chemotherapy
   2.6.3 Hormonal Therapies
   2.6.4 Targeted Therapies
   2.6.5 Types of Cancer Vaccines

3 Key Marketed Products
3.1 Overview
3.2 Gardasil/Gardasil 9
3.3 Provenge
3.4 Cervarix
3.5 Imlygic
3.6 DCVax-L
3.7 Recombivax HB
3.8 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
   4.2.1 Therapeutic Vaccine Molecule Type and Development Stage
   4.2.2 Prophylactic Vaccine Molecule Type and Development Stage
   4.2.3 Key Oncology Indications by Molecule Type and Development Stage
4.3 Pipeline by Molecular Targets and Indication
   4.3.1 Therapeutic Vaccine Molecular Targets
4.4 Clinical Trials
   4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
   4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
   4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
   4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
   4.5.1 Tisagenlecleucel-T (CTL-019) - Novartis
   4.5.2 KTE-C19 - Kite Pharma
   4.5.3 JCAR017 - Juno Therapeutics
   4.5.4 JCAR015 - Juno Therapeutics
   4.5.5 bb-2121 - Bluebird Bio
   4.5.6 Prostvac - Bavarian Nordic
   4.5.7 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Kite Pharma
4.5.8 Conclusion
5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Prophylactic and Therapeutic Vaccine Market Split
5.3 Revenue Forecast by Molecular Target
5.3.1 HPV L1 Major Capsid Protein
5.3.2 Hepatitis B Surface Antigen
5.3.3 Cluster of Differentiation
5.3.4 Granulocyte Macrophage Colony Stimulating Factor
5.3.5 Tumor Necrosis Factor Receptor Superfamily Member
5.3.6 Prostatic Acid Phosphatase

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Merck & Co - How Will Cancer Vaccine Revenues Be Affected by Recombivax HB's Patent Expiry?
6.1.2 GSK - How Will Its Prophylactic Vaccines Fair Against Merck & Co's Competitors?
6.1.3 Novartis - How Will This Top 20 Company Perform in The Cancer Vaccines Market?
6.1.4 Kite Pharma - Could it Develop a Blockbuster?
6.1.5 Amgen - How Will Recent Approval Imlygic Perform?
6.1.6 Juno Therapeutics - Great Potential for its CD19 Targeting Therapies
6.1.7 Valeant Pharma - Uncertain Times and Financial Difficulties
6.1.8 Bluebird Bio - How Will This Small Company Perform in the Cancer Vaccines Market?
6.1.9 Bavarian Nordic - How Will Prostvac Perform?
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Deals by Indication, Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region and Value
7.2.2 Deals by Indication, Stage of Development and Value
7.2.3 Deals by Molecule Type, Molecular Target and Value
7.2.4 Table for Co-development Deals With a Disclosed Value

8 Appendix
8.1 References
8.2 Table of All Pipeline Products
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables
Table 1: Cancer Vaccines Market, Global, Symptoms of Key Indication Cancers, 2016
Table 2: Cancer Vaccines Market, Global, Infectious Agents and Associated Cancers, 2016
Table 3: Cancer Vaccines Market, Global, Epidemiology of Key Oncology Indications, 2016
Table 4: Cancer Vaccines Market, Complications Associated with Cervical, Liver, Melanoma and Prostate Cancers, 2016
Table 5: Cancer Vaccines Market, Optimal Chemotherapy Usage Rates
Table 6: Cancer Vaccines Market, Global, Approved Indications for Gardasil, 2016
Table 7: Cancer Vaccines Market, Global, Approved Indications for Provenge, 2016
Table 8: Cancer Vaccines Market, Global, Approved Indications for Cervarix, 2016
Table 9: Cancer Vaccines Market, Global, Approved Indications for Imlygic, 2016
Table 10: Cancer Vaccines Market, Global, Approved Indications for DCVax-L, 2016
Ordering: 

Order Online - [http://www.researchandmarkets.com/reports/3978520/](http://www.researchandmarkets.com/reports/3978520/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets, 
Guinness Centre, 
Taylors Lane, 
Dublin 8, 
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 |
| Web Address: | http://www.researchandmarkets.com/reports/3978520/ |
| Office Code: | SC2GBNB5 |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World